U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 278 results

Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ABSOLUTE)



Sodium artesunate, an artemisinin derivative, is used in malaria treatment. Artesunate, has been licensed in Thailand for the treatment of falciparum malaria since 1990. It is a potent antimalarial drug that can reduce parasitaemia by 90% within 24 h...
Status:
US Approved Rx (2015)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata. Trabectedin was approved for the treatment of liposarcoma or leiomyosarcoma (USA and Europe) and ovarian cancer (only in Europe). Trabectedin exe...
Status:
US Approved Rx (2015)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Bendamustine, brand name Treanda, is a chemotherapeutic agent that displays a unique pattern of cytotoxicity compared with conventional alkylating agents. Treanda is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), in ...
Status:
US Approved Rx (2013)
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)



Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon admin...
Status:
US Approved Rx (2022)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Arranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleoti...
Status:
US Approved Rx (2018)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:

Conditions:

BARACLUDE® is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It inhibits all three steps in the viral replication process. By competing with the natural substrate deoxyguanosine t...
Status:
US Approved Rx (2017)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Clofarabine is a anti-cancer drug which was approved by FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. After crossing the cell membrane the drug is rapidly metabolized by deoxycytidine kinase to ...
Status:
US Approved Rx (2004)
First approved in 2004

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Tinidazole is a synthetic antiprotozoal agent, formally known as 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole and a second-generation 2-methyl-5-nitroimidazole. Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is...
Status:
US Approved Rx (2020)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disord...
Status:
US Approved Rx (2017)
First approved in 2002

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:


Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluoroura...